Most Read Articles
Roshini Claire Anthony, 6 days ago

Women who receive a single dose of amoxicillin and clavulanic acid within 6 hours of operative vaginal delivery could significantly reduce their postpartum infection risk, according to the UK-based ANODE* trial.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
Audrey Abella, 05 Jul 2018
The addition of the sodium-glucose cotransporter-2 inhibitor ertugliflozin to metformin improved glycaemic control, body weight, and blood pressure (BP) in patients with inadequately controlled type 2 diabetes (T2D), according to the results of the VERTIS MET* trial presented at ADA 2018.
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.

Use of antiparkinsonian medication tied to acquired premature ejaculation

06 Jun 2018

Individuals taking antiparkinsonian drugs have developed ejaculatory dysfunction, which suggests a possible medication effect, in a case series of Parkinson’s disease (PD) patients with acquired premature ejaculation (PE).

The mean age of PD onset was 53.3±12.7 years (range, 38–77 years), while sexual problems started to appear 4.0±3.1 years later. Patients had a mean 7.3 min (range, 2–20 min) of intravaginal ejaculation latency (IELT) before the onset of acquired PE.

Of note, there was an abrupt appearance of the ejaculatory dysfunction as characterized by a dramatically shortened IELT in all patients. Furthermore, three patients had an ejaculation prior to vaginal penetration, which hampered sexual intercourse.

In some patients, two additional sexual problems occurred: four had erectile dysfunction, five had libido changes, four had increase desire and one had reduced desire.

In this study, the investigators described eight PD patients who asked for a sexological consultation between 2008 and 2014 because of new-onset of PE. Patients were diagnosed with acquired PE according to the DSM-V criteria and the International Society for Sexual Medicine committee. Demographic, medical and sexual-related data of patients were retrieved and analysed.

Acquired PE is defined as “a male sexual dysfunction characterized by the development of a clinically significant and bothersome reduction in ejaculation latency time in men with previous normal ejaculatory experiences, often to about 3 minutes or less, the inability to delay ejaculation on all or nearly all vaginal penetrations, and the presence of negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy.” [Transl Androl Urol 2016;5:434-449]

“PE has been reported in 40.6–51.5 percent of men affected by PD,” the investigators said. “However, this nonmotor sexual complaint has not been studied in detail.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 6 days ago

Women who receive a single dose of amoxicillin and clavulanic acid within 6 hours of operative vaginal delivery could significantly reduce their postpartum infection risk, according to the UK-based ANODE* trial.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
Audrey Abella, 05 Jul 2018
The addition of the sodium-glucose cotransporter-2 inhibitor ertugliflozin to metformin improved glycaemic control, body weight, and blood pressure (BP) in patients with inadequately controlled type 2 diabetes (T2D), according to the results of the VERTIS MET* trial presented at ADA 2018.
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.